IVERIC bio, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2015-11-05: Form 8-K; Period of report 2015-11-05; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2015-09-10: Form 8-K; Period of report 2015-09-03; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2015-08-05: Form 8-K; Period of report 2015-08-05; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2015-07-28: Form 8-K; Period of report 2015-07-27; Description 2.02 Results of Operations and Financial Condition; 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2015-11-05 | 8-K | 2015-11-05 | 2.02 Results of Operations and Financial Condition | 2.02 On November 5, 2015, Ophthotech Corporation announced its financial results for the quarter ended September 30, 2015. | a15-22402_18k.htm |
| 2015-09-10 | 8-K | 2015-09-03 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | a15-19223_18k.htm |
| 2015-08-05 | 8-K | 2015-08-05 | 2.02 Results of Operations and Financial Condition | 2.02 On August 5, 2015, Ophthotech Corporation announced its financial results for the quarter ended June 30, 2015. | a15-16962_18k.htm |
| 2015-07-28 | 8-K | 2015-07-27 | 2.02 Results of Operations and Financial Condition; 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review | 2.02 The disclosure set forth in Item 4.02 below is incorporated by reference. 4.02 On July 27, 2015, the Audit Committee (the “Audit Committee”) of the Board of Directors of Ophthotech Corporation (the “Company”), in consultation with management and discussion with the Company’s independent registered public accounting firm, Ernst & Young LLP (“E&Y”), concluded that the Company’s unaudited financial statements for the quarters ended June 30, 2014, September 30, 2014 and December 31, 2014, its audited financial statements for the year ended December 31, 2014 and its unaudited financial statements for the quarter ended March 31, 2015 (the “Relevant Financial Statements”), incorrectly accounted for certain valuation allowances related to deferred tax assets. | a15-16433_18k.htm |
| 2015-07-21 | 8-K | 2015-07-20 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On July 20, 2015, Ophthotech Corporation (the “Company”) and Todd N. Smith, the Company’s Senior Vice President and Chief Commercial Officer, entered into a Separation Agreement and General Release (the “Separation Agreement”), pursuant to which, Mr. Smith’s employment with the Company will end on July 31, 2015. | a15-16012_18k.htm |
| 2015-06-04 | 8-K | 2015-06-04 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 Ophthotech held its Annual Meeting of Stockholders on June 4, 2015. | a15-13531_18k.htm |
| 2015-05-11 | 8-K | 2015-05-11 | 2.02 Results of Operations and Financial Condition | 2.02 On May 11, 2015, Ophthotech Corporation announced its financial results for the quarter ended March 31, 2015. | a15-11314_18k.htm |
| 2015-04-14 | 8-K | 2015-04-08 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | a15-9129_18k.htm |
| 2015-02-23 | 8-K | 2015-02-23 | 2.02 Results of Operations and Financial Condition | 2.02 On February 23, 2015, Ophthotech Corporation announced its financial results for the quarter and year ended December 31, 2014. | a15-5160_18k.htm |